



IL-15 Improves Aging-Induced Persistent T Cell Exhaustion in Mouse Models of Repeated Sepsis

Saito, Masafumi ; Inoue, Shigeaki ; Yamashita, Kimihiro ; Kakeji, Yoshihiro ; Fukumoto, Takumi ; Kotani, Joji

(Citation)

Shock, 53(2) :228-235

(Issue Date)

2020-02

(Resource Type)

journal article

(Version)

Accepted Manuscript

(Rights)

© 2019 by the Shock Society

(URL)

<https://hdl.handle.net/20.500.14094/90008020>



1 **(a) Manuscript title**

2 IL-15 improves aging-induced persistent T cell exhaustion in mouse models of repeated sepsis

3 **(b) Author's name and affiliation**

4 Masafumi Saito^{1,2}, Shigeaki Inoue^{1,2*}, Kimihiro Yamashita³, Yoshihiro Kakeji³, Takumi

5 Fukumoto⁴, Joji Kotani²

6 1. Department of Emergency and Critical Care Medicine, Tokai University School of

7 Medicine

8 2. Department of Disaster and Emergency and Critical Care Medicine, Kobe University

9 Graduate School of Medicine

10 3. Kobe University Division of Gastrointestinal Surgery Department of Surgery Graduate

11 School of Medicine Kobe Japan

12 4. Department of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of

13 Medicine, Kobe, Japan

14 **(c) Corresponding author**

15 *Shigeaki Inoue

16 Professor

17 Dept of Disaster and Emergency Medicine Kobe University. Graduate School of Medicine

18 Kusunoki-cho 7-5-2, Chuo-ward, Kobe, Japan

19 Tel: +81-78-382-6521; Fax: +81-78-341-5254; E-mail: inoues@med.kobe-u.ac.jp

20 **(d) Conflict interest**

21 The authors have no conflict of interest.

22 **(e) Running head**

23 IL-15 improves persistent T cell exhaustion

24

25

ABSTRACT

26 Aging is a grave problem in sepsis, and T cell exhaustion is the main cause of sepsis-induced
27 immunosuppression. Sepsis- and aging-induced T cell exhaustion is related to secondary infection
28 with a poor long-term outcome in the elderly. However, the trend, impact, and mechanism of T
29 cell exhaustion are still unclear. Interleukin (IL)-15 improves survival rate of septic mice via its
30 anti-apoptotic effect on T cells, however, it's still unclear how IL-15 reverses prolonged T cell
31 exhaustion in aged septic mice. The purpose of this study was to clarify the trend of sepsis-
32 induced T cell exhaustion and whether IL-15 prevents aging-induced persistent T cell exhaustion
33 in septic mice. Preserved cecal slurry was injected intraperitoneally into young (6-week-old) and
34 aged mice (18- to 24-month-old) four times, to induce clinically-relevant repeated sepsis. IL-15
35 (1.5 μ g) or PBS was injected subcutaneously three times, body weight was serially measured, and
36 peripheral blood cells from their cheek were serially collected for 50 days. Sepsis-induced T cell
37 exhaustion was significantly severe in aged mice than in young mice and was accompanied with
38 decreased naïve CD4⁺ and CD8⁺ T cells ($p < 0.01$) and increased expression of program death 1
39 on T cell ($p < 0.01$) and regulatory T cell population ($p < 0.01$). IL-15 significantly improved
40 sepsis-induced T exhaustion, with significantly increased numbers of NK cells and macrophages,

41 and significantly enhanced phagocytosis activity in aged septic mice ($p < 0.05$). It decreased the
42 long-term mortality associated with sepsis survivors by improving T cell exhaustion over an
43 extended duration and also ameliorated aging-induced persistent T cell exhaustion in septic mice.
44

INTRODUCTION

45

46

47 Sepsis is defined as a life-threatening condition associated with multi-organ dysfunction
48 originating due to the dysregulated innate immune response against pathogen infections (1) and
49 affects more than 19 million people each year (2). Nearly 60% septic patients are ≥ 65 years of
50 age (3), and their 3-month survival rate is significantly low than that of adult patients aged 18-64
51 years (4). Advances in treatment at intensive care unit (ICU) have improved the short-term
52 prognosis of sepsis patients; however, sepsis continues to have a poor prognosis especially in
53 elderly patients.

54 Several studies revealed that sepsis can cause immunosuppression, which may lead to ICU-
55 acquired infections. Elderly septic patients have secondary infections at 2 to 4 weeks after initial
56 ICU admission (5). In line with this evidence, reduced number of immunocompetent T cells and
57 persistent lymphopenia were observed in elderly septic patients (6). They also displayed increased
58 numbers of circulating regulatory T cells (Treg), which negatively regulate the host immune
59 response, and expression of programmed death-1 (PD-1) on these T cells. This phenomenon of T
60 cell dysfunction induced by sepsis is called "T cell exhaustion" (7), which appears to be more

61 severe in elderly patients. However, the precise mechanisms of induction of severe and persistent
62 T cell exhaustion in elderly septic patients and recovery from this status are not known and are
63 immunotherapeutic targets in sepsis (8-9).

64 Interleukin (IL)-15 is an attractive therapeutic target in sepsis because it plays an essential
65 role in the development and homeostasis of naive CD8⁺ T cells, memory T cells and natural killer
66 (NK) cells, which have a key role in pathogen elimination (10-13). In addition, our previous study
67 revealed that IL-15 inhibited CD8⁺ T cell apoptosis and improved survival rate in septic mice (14).

68 Although very few studies have been conducted, the above mentioned facts indicate the
69 contributory role of IL-15 to improve T cell exhaustion on a long-term prognosis. Clinically
70 relevant septic model was induced by using cecal slurry (CS) model, which is established by
71 Wynn et al. (15) and modified by Starr et al. (16) in this study. Cecal ligation and puncture (CLP)
72 is regarded as the “gold standard” for establishing an experimental sepsis model in rodents
73 because it closely mimics the clinical course of intra-abdominal sepsis. However, variability in
74 this model has been shown as severity of sepsis is highly dependent on the cecal content (e.g
75 quantity or microflora), wound-healing capability, skill of the researcher (e.g accuracy or rapidity),
76 etc. (15, 17). Unlike CLP model, CS model can induce intra-abdominal sepsis by injection of

77 suspended cecum contents, therefore, this model may have high reproducible method regardless
78 of the skill of researcher or individuality of mice. This advantage of in CS method enables us to
79 mimic the repeated clinically-relevant infection with minimally invasive technique on mice.

80 The first purpose of this study was to clarify the trend of sepsis-induced T cell exhaustion
81 among young and aged mice with clinically-relevant repeated sepsis over 50 days. The second
82 purpose was to investigate the effects of IL-15 on sepsis-induced T cell exhaustion in young and
83 aged septic mice over an extended duration.

84

85

MATERIALS AND METHODS

86

87 *Chemicals and recombinant mouse IL-15*

88 Ammonium chloride (NH₄Cl), Tris-hydroxymethyl aminomethane (Tris-HCl) and glycerol
89 were purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan). Bovine serum albumin
90 (BSA) was purchased from Nacali Tesque (Kyoto, Japan). Recombinant mouse IL-15 was
91 purchased from PeproTech (Rocky Hill, NJ, USA).

92 *Antibodies (Abs)*

93 All Abs were purchased from Biolegend (San Diego, CA, USA). Mouse Abs used for this
94 were as follows: PerCP/Cy5.5-conjugated mouse anti-CD4, PerCP/Cy5.5-conjugated mouse anti-
95 NK1.1, APC/Cy7-conjugated mouse anti-CD8, APC/Cy7-conjugated mouse anti-F4/80,
96 fluorescein isothiocyanate (FITC)-conjugated mouse anti-CD25, FITC-conjugated mouse anti-
97 Ly6C, PE-conjugated mouse anti-CD62L, PE/Cy7-conjugated mouse anti-CD279 (Programed
98 death-1; PD-1), APC-conjugated mouse anti-CD127 (IL-7 Receptor- α), APC-conjugated mouse
99 anti-CD11b, and Pacific blue-conjugated mouse anti-Ly6G. Mouse Fc-blocker was procured from
100 BD Pharmingen (San Jose, CA, USA).

101 *Animals and housing*

102 **Experiment 1.** Young (5-weeks old; n = 19) and aged (18-24 months old; n = 19) female
103 C57BL6/J mice were obtained from CLEA Japan, Inc. (Tokyo, Japan). The mice were housed in
104 groups of 4 to 6 per cage and allowed to acclimatize for a week before the initiation of the test.
105 Mice were maintained under specific pathogen-free conditions with a 12 h light-dark cycle in the
106 Department of Laboratory Animal Science at Tokai University. The experimental protocol was
107 approved by the Institutional Animal Care and Use Committee at Tokai University (#181068 and
108 #181070). All experiments followed the recommendations of the International Expert Consensus
109 Initiative for Improvement of Animal Modeling in Sepsis as previously described (18).

110 **Experiment 2.** In another experimental set, young female and male (5-weeks old; 10
111 females, 10 males) and 18-month old female C57BL6/J mice (n = 10) were obtained from CLEA
112 Japan, Inc. (Tokyo, Japan). The mice were housed in groups of four per cage and allowed to
113 acclimatize for a week before the initiation of the test. Mice were maintained under specific
114 pathogen-free conditions with a 12-h light-dark cycle in the Department of Laboratory Animal
115 Science at Kobe University. The experimental protocol was approved by the Institutional Animal
116 Care and Use Committee at Kobe University (#P180806-R1).

117 ***Preparation of cecal slurry***

118 Cecal slurry (CS) was prepared as described previously by Starr et al. (16). Briefly, male
119 ICR mice (6 to 8 week old) were scarified and whole cecums were harvested. Mice cecums were
120 snicked, transferred to nylon-mesh bag, 1 - 2 mL of sterile water was poured and filtered twice.
121 The mixture was collected and centrifuged at 11,000 rpm for 1 min. The supernatant was
122 discarded and the residue was suspended in 30% glycerol with a final concentration 0.5 mg/mL.
123 CS (400 to 500 μ L) was transferred to cryotubes and stored at -80 $^{\circ}$ C till use.

124 ***Study design***

125 **Experiment 1.** CS (50 μ L) was injected four times peritoneally into young (5-weeks old;
126 n = 19) and aged (18-24 months old; n = 19) female mice on day 0, 4, 7 and 10 to induce sepsis,
127 and simultaneously 1.5 μ g of IL-15 or PBS was also injected consecutively three times on day 3,
128 7 and 10 (Figure 1A). Body weight was serially measured, and peripheral blood cells were
129 collected from their cheek nine times within 50 days.

130 **Experiment 2.** Young female and male mice and aged female mice were sacrificed at day
131 12. PBMCs and spleen were harvested to investigate cell population dynamics. Peritoneal lavage
132 was also collected from each mouse to investigate the phagocytic capacity of peritoneal

133 macrophages and to estimate bacterial load. This experiment was conducted as described in
134 Figure 1A, except for the timing of sacrifice (Supplemental Figure 1A).

135 ***Phagocytosis assay***

136 The mice were anesthetized and their peritoneal lavage fluid was collected with 10 mL of
137 phosphate buffered saline containing 0.1% BSA (0.1% BSA /PBS). Peritoneal exudate cells
138 (2×10^5 /100 μ L) were incubated with 100 μ L of 0.2 mg/ml pHrodoTM *Escherichia coli*
139 BioParticlesTM conjugate for phagocytosis (REF:P35361; Life Technologies, Carlsbad, CA,
140 USA) for 30 min at 37°C. After a 10-min incubation with Fc blocker, the cells were stained to
141 identify F4/80⁺ macrophages and the expression of intra-cellular PE-labeled *E. coli* was
142 quantified by flow cytometry using a FACS Verse device (BD Biosciences, San Jose, CA,
143 USA).

144 ***Bacterial colony counting***

145 The mice were anesthetized and lavage of their peritoneal cavities was carried out using
146 10 mL of warm saline on day 12. Peritoneal lavage fluids were placed in sterile vials and equal
147 volumes were used for bacterial culture. Ten-fold serial dilutions of each lavage fluid were made
148 and cells were plated; next, colonies were counted after 24 h of incubation.

149 ***Flow cytometric analysis of murine T cell, NK cell and macrophage distribution***

150 Blood samples were collected from mice cheek, and murine peripheral blood mononuclear
151 cells (PBMC) were isolated by density gradient cell separation using Histopaque1083TM (Sigma-
152 Aldrich, St Louis, MO, USA). Separated PBMC were treated with red blood cell lysis buffer

153 containing 139.5 mM NH₄Cl and 1.7 mM Tris-HCl (pH 7.65) at 37°C for 10 min, and then washed
154 with 0.1% BSA /PBS. Murine PBMC were incubated with Abs mixture for 30 min at 4°C after
155 treating with mouse Fc-blocker to block non-specific binding sites. Stained cells were analyzed
156 using FACS Verse. The proportion of the designated cell fraction was determined by recording
157 10,000 events (Figure 1B), and data files were analyzed using the FlowJo software (Tree Star,
158 OR, USA).

159 Mice were gently sacrificed by cervical dislocation under anesthesia after peripheral blood
160 samples had been collected. Each spleen was surgically removed and separated by gently pressing
161 the organs through a 70-micron filter. The collected spleen cells were washed using 0.1%
162 BSA/PBS washed and the red blood cells were lysed as well as the blood samples. After treating
163 with mouse Fc-blocker, the spleen cells were incubated with the mixture of Abs for 30 min at 4°C
164 and analyzed using the FACS Verse device.

165 Collected mouse peritoneal lavage fluids were aseptically collected, treated with red blood
166 cell lysis buffer at 37°C for 10 min, and centrifuged at 300×g for 5 min. The samples were washed
167 with 0.1% BSA /PBS and incubated with the mixture of Abs for 30 min at 4°C after treating with
168 mouse Fc-blocker. Stained cells were analyzed using the FACS Verse device.

169 *Statistical analysis*

170 Statistical analysis was performed using the EZR statistical software (19). Group
171 differences in body weight and T cell distribution were assessed by repeated-measures ANOVA.
172 For survival studies, a log rank test was used. $P < 0.05$ was considered as statistically significant.
173 Results are presented as mean \pm SD. Two-way analysis of variance (ANOVA) was performed to
174 determine the main effects of IL-15 (treated versus non-treated mice) and age (young versus aged),
175 as well as the interaction between these two factors.

176

177

RESULTS

178 *Aging induced lower body weight and survival rate in clinically-relevant repeated sepsis model*

179 To investigate sepsis-induced chronic immunosuppression in Experiment 1, a repeated
180 sepsis model was established by injection of CS into mice (Figure 1A). The reaction produced
181 was characteristic of the induction of mild inflammatory responses. Body weight drastically
182 decreased after the initial injection of CS in both young and aged mice. However, unlike that in
183 aged septic mice, body weight of young mice was recovered until day 10 after the initial injection
184 of CS. Notably, administration of IL-15 prevented the initial reduction of body weight in young
185 septic mice at day 3 (Figure 1B). In the case of aged septic mice, their body weight loss persisted
186 for over 50 days (Figure 1B). Although IL-15 administration attenuated persistent body weight
187 loss in aged septic mice, there were no statistically significant differences with or without IL-15
188 administration.

189 Survival rates in young slurry and aged slurry group mice were 91.7% (11/12) and 69.2%
190 (9/13) respectively (Figure 1C). All IL-15-administered mice survived, but the differences in with
191 or without IL-15 administration groups were not statistically significant (young mice: $p = 0.41$;
192 aged mice: $p = 0.15$; Figure 1C).

193 ***IL-15 reversed aging-induced CD4⁺ and naïve CD4 T cell reduction in septic mice***

194 To investigate whether IL-15 administration influenced CD4⁺ T cells in septic mice, we
195 monitored CD4⁺ T cell and subpopulations in peripheral blood (Figure 2A). As shown in Figure
196 2B, the distribution of CD4⁺ T cell was consistently lower in aged septic mice for at least 50 days
197 than in young septic mice ($p < 0.01$). Although CD4⁺ T cells were observed, and the frequencies
198 were not significantly different between two young septic mice groups ($p = 0.07$), the IL-15-
199 treated aged septic mice showed a significant increase in CD4⁺ T cells than non-treated mice (p
200 $= 0.03$). In addition, in both IL-15-treated young and aged septic mice, naïve CD4⁺ T cell
201 population was significantly higher than that in non-treated mice (young mice: $p < 0.01$; aged
202 mice: $p < 0.01$; Figure 2C).

203 ***IL-15 inhibited aging-induced increase of PD-1 on CD4⁺ T cells and Treg in septic mice***

204 To investigate whether IL-15 improves sepsis-induced T cell exhaustion, we analyzed the
205 population of PD-1⁺ CD4⁺ T cells and Treg cells, which are well known hallmarks of T cell
206 exhaustion. Flow cytometric analysis revealed that PD-1⁺ CD4⁺ T cell population drastically
207 increased after primary injection of CS in both aged and young septic mice (Figure 2D). PD-1
208 expression was sustained in CD4⁺ T cells of aged septic mice as compared to young septic mice

209 (Figure 2D). In addition, Treg population as well as PD-1⁺CD4⁺ T cells of aged septic mice were
210 also consistently higher than those in young septic mice ($p < 0.01$; Figure 2E). Meanwhile, IL-15
211 inhibited the increase in these cell populations especially in aged septic mice. PD-1⁺CD4⁺ T cell
212 population was consistently low in IL-15-administered aged septic mice as compared with aged
213 slurry mouse group. Importantly, in this group, PD-1⁺CD4⁺ T cells were significantly down-
214 regulated at day 3 after the initial injection of CS ($p < 0.01$; Figure 2D). Furthermore, Treg cell
215 population was also consistently down-regulated in IL-15-administered aged septic mice
216 compared to non-treated aged septic mice ($p < 0.01$; Figure 2E).

217 ***IL-15 reversed aging-induced naïve CD8 T cells reduction in septic mice***

218 We examined whether IL-15 prevents CD8⁺ T cell exhaustion in septic mice over an
219 extended duration. In young septic mice, the frequency of CD8⁺ T cell population upon IL-15-
220 administration was consistently higher than that in not-treated young septic mice ($p = 0.03$; Figure
221 3A). In contrast, IL-15 did not influence the frequency of CD8⁺ T cells in the peripheral blood of
222 aged septic mice ($p = 0.91$; Figure 3A). In addition, the frequency of naïve CD8 T cells was
223 significantly higher in IL-15-treated aged septic mice in comparison with non-treated aged septic
224 mice group ($p < 0.01$, Figure 3B), as well as in young septic mice ($p < 0.05$, Figure 3B).

225 ***IL-15 inhibited aging-induced increase of PD-1⁺ CD8⁺ T cells population in aged septic mice***

226 Flow cytometric analysis revealed that PD-1⁺CD8⁺ T cell population drastically increased
227 after primary injection of CS in both aged and young septic mice, as well as PD-1⁺CD4⁺ T cell
228 (Figure 3C). Although PD-1⁺ CD8⁺ T cell was not significantly difference in young septic mice,
229 this cell population was down-regulated in IL-15-administered aged septic mice compared to non-
230 treated aged septic mice ($p < 0.01$; Figure 3C). All the results are summarized in Table 1.

231 ***IL-15 up-regulated splenic CD4⁺ T cell and NK cells in aged septic mice***

232 To investigate whether IL-15 effects splenic immune cells in septic mice, we sacrificed
233 young and aged septic mice 12 days after the initial injection of CS in Experiment 2
234 (Supplemental Figure 1A). The frequency of splenic CD4⁺ T cells was significantly higher in IL-
235 15-treated mice in both young and aged mice in comparison with the non-treated group ($p < 0.05$,
236 Supplemental Figure 1B). Although CD8⁺ T cells tended to increase in the spleens of IL-15-treated
237 mice, no significant difference was evident ($p = 0.07$, data not shown).

238 IL-15 activates and maintains NK cells (10-13). Thus, we next investigated whether IL-15
239 could increase NK cells in aged septic mice on day 12. As we anticipated, flow cytometry analysis
240 revealed a significant increase in NK cells in spleens of IL-15-treated aged septic mice compared

241 to non-treated mice ($2.5 \pm 0.1\%$ vs $2.0 \pm 0.4\%$, $p = 0.02$; Supplemental Figure 1B). In addition,
242 IL-15 tended to increase the frequency of NK cells in PBMCs in aged female mice. However, the
243 increase was not statistically significant ($6.2 \pm 3.9\%$ vs $2.4 \pm 0.9\%$, $p = 0.11$, data not shown). We
244 also investigated the expression of markers of activated NK cells (CD25, CD69, and CD107a).
245 The expressions of these markers were not significantly different when IL-15 was administered
246 or not administered in both young and aged septic mice (data not shown).

247 ***IL-15 increased circulate macrophage and enhanced phagocytosis activity in aged septic mice***

248 We examined the phagocytic activity and bacterial clearance in IL-15 treated mice. First,
249 we analyzed the distribution of macrophages in PBMCs in septic mice. We observed that the
250 frequency of macrophages was statistically different between young and aged septic mice (p
251 < 0.01 , Supplemental Figure 1C). Moreover, significantly more circulating macrophages were
252 evident in IL-15-treated aged septic mice than in non-treated aged mice ($p = 0.03$, Supplemental
253 Figure 1C). We next examined whether IL-15 affected phagocytic activity, which was defined as
254 the percentage of cells with one or more engulfed PE-conjugated *E. coli* beads within the
255 phagocytic cell population in peritoneal lavage. The phagocytic activity of aged mice was
256 significantly reduced compared to young septic mice ($p < 0.01$, data not shown). The phagocytic

257 cell population was significantly enhanced in IL-15-treated aged septic mice in comparison with
258 non-treated aged septic mice ($p = 0.01$, Supplemental Figure 1B). Finally, we investigated the
259 effectiveness of IL-15 on bacterial colony formation. No bacterial colonies formed after 24 h
260 storage at 37°C of peritoneal lavage of IL-15-treated aged septic mice. However, there was no
261 statistically significant difference between the treated and non-treated groups (Supplemental
262 Figure 1E).

263 We sought to determine the levels of IL-6, IL-10, interferon-gamma (IFN- γ), and tumor
264 necrosis factor-alpha (TNF- α) in the plasma of septic mice using cytometric bead flow cytometry
265 assay. However, these cytokines were under the limit of detection in all mice in this model (data
266 not shown).

267

DISCUSSION

268

269

270 Changes in T cell function and the relative proportions with aging are well known, and
271 these age-related immunological changes involve the decline of immune response against new
272 pathogens in elderly people (20-21). Consistent with this evidence, our results revealed that the
273 frequency of CD4⁺ T cells and naïve CD4⁺ T cells in aged mice significantly decreased in
274 comparison with young mouse at day 0 (Figure 2B and 2C). Additionally, we also showed that
275 the frequency of PD-1 expressing CD4 and Treg (Figure 2D and 2E) and CD8 T cell (Figure 3B
276 and 3C) was significantly higher in aged mouse than in young mouse. These findings imply that
277 aging is associated with increased susceptibility to and severity of infection.

278 Recent studies reported that sepsis is associated with a greater risk of long-term mortality
279 (22-24). Interestingly, Prescott et al. reported only a 5-year survival rate of 20% for severe sepsis
280 patients (24). One of the main reasons of long-term mortality in sepsis is a persistence of T cell
281 exhaustion. In addition, our previous studies demonstrated that T cell exhaustion is one of the
282 causes in elderly sepsis patients suffering from secondary infections (4-5). Therefore, establishing
283 strategies to rescue T cell exhaustion is important to prevent long-term mortality on sepsis (7-8).

284 Hence, our data is important to provide evidence that sepsis-induced T cell exhaustion might be
285 more prolonged than previously assumed. In the case of young septic mice, their body weight and
286 CD8⁺ T cell populations were recovered for 50 days (Figure 1B and 3A). On the contrary, CD4⁺
287 T cells of young septic mice were only recovered to approximately 81% of the initial frequency
288 on the last day (day0: 45.6 ± 2.4% → day50: 37.0 ± 2.8%, Figure 2B). These results indicate that
289 host immune function needs time to recover from sepsis induced T cell exhaustion even in young
290 mice. In aged septic mice, we observed consistent reduction of CD4⁺ and CD8⁺ T cells (Figure
291 2B and 3A), and up-regulation of Treg and PD-1⁺ T cells during 50 days (Figure 2D, 2E and 3C).
292 These results suggest that elderly septic mice show severe and prolonged T cell exhaustion than
293 young septic mice, leading to secondary infection after sepsis in elderly survivors. Rossi et al.
294 have published several studies regarding lymphopenia with skewed differentiation of
295 hematopoietic stem cells in the elderly (25-26). This age-dependent skewed distribution of aged
296 HSCs may be related to the reduction of T cells in the elderly.

297 The term exhaustion has been used to describe the state of functional unresponsiveness,
298 replicative senescence, and ultimate physical deletion of T cells during chronic infection in mice
299 and humans (4,7,27). It is also well known that the population of PD-1⁺CD4⁺ T cells increases

300 with aging (28). This T cell anergy retains the capacity to produce low levels of cytokine such as
301 IL-2 and interferon- γ (29), explaining one of the reasons why elderly people have high
302 susceptibility to infection. However, our study revealed that sepsis increased PD-1 expression for
303 only a limited period of time during CS injection; the frequency of this cell population increased
304 after initial injection of CS, and maintained at high level up to day 10, but decreased and returned
305 to initial level by day 14 (Figure 2D, and 3C). On the contrary, the frequency of circulating Treg
306 was maintained at a consistently high level in both young and aged mice with CS-induced sepsis
307 during the period (Figure 2E). Recent studies have shown that Treg is the main contributor to the
308 induction and maintenance of immunosuppression (30-31), rather than PD-1 expression on T cells
309 during sepsis. Taken together, these results suggest that the PD-1 expressed T cell population
310 might have only a limited contribution to sepsis-induced “persistent” T cell exhaustion, whereas
311 Treg cell is the one of the key players in the persistent T cell exhaustion. Since our data showed
312 that IL-15 could inhibit a consistently high level of Treg distribution in peripheral blood in both
313 young and aged septic mice (Figure 2E), IL-15 has a potential to improve sepsis-induced
314 persistent T cell exhaustion and reinvigorate immune response against pathogens in aged mice.
315 Nascimento et al. revealed that IL-33 has a major function in the induction of sepsis-induced long-

316 term immunosuppression via expansion of Treg, type 2 macrophages, and type 2 innate lymphoid
317 cells (31). Therefore, we further examined whether IL-15 was associated with the production of
318 Treg inducible cytokines like IL-10, IL-33, and transforming growth factor- β , and how IL-15 can
319 inhibit the expansion of Treg populations during sepsis.

320 IL-15 is secreted primarily by dendritic cells, monocytes, and epithelial cells during
321 infection. Since it shows IL-2-like activity, IL-15 is not only essential for development and
322 activation on T cells and NK cells (10-13), but also it can prevent sepsis-induced T cell apoptosis
323 by regulating of apoptotic associated molecules (14). Thus, it has attracted attention as a potential
324 therapeutic for patients with chronic infection including sepsis (14). In fact, no deaths occurred
325 in IL-15-treated young and aged septic mice (Figure 1C). In addition, IL-15 significantly inhibited
326 reduction of CD4⁺ T cell (Figure 2B), and continuously up-regulated naive CD4⁺ and CD8⁺ T cell
327 in aged septic mice after injection of CS (Figure 2C and 3B). Furthermore, PD-1 expression was
328 suppressed on CD4⁺ and CD8⁺ T cells, and Treg cell expansion by IL-15 treatment in aged septic
329 mouse group (Figure 2D, 2E and 3C). Taken together, IL-15 could improve sepsis-induced T cell
330 exhaustion on long-term prognosis and reinvigorate immune response against pathogen in aged
331 mice, and it might prevent and reduce the risk of secondary infection.

332 Recent studies have revealed that PD-1 signaling inhibits phosphoinositide 3-kinase
333 (PI3K)/protein kinase B (Akt) pathway, which is involved in T cell proliferation, development
334 and activation, and results in T cell dysfunction (32). On the other hand, IL-15 activates PI3K/Akt
335 pathway via activation of Janus kinase (JAK)-3/Signal transducers and activators of transcription
336 (STAT)-5 pathway in lymphocyte (33). We further examine whether IL-15 up-regulates Akt
337 phosphorylation on exhausted T cells. It is still unclear why administration of IL-15 in acute phase
338 of sepsis improve aging-induced long-term persistence of T cell exhaustion. We did not anticipate
339 that IL-15 would inhibit sepsis-induced immunosuppression over an extended duration because
340 it has a short half-life *in vivo* (34). As clinically important, administration of IL-15 in acute phase
341 of sepsis could prevent the sepsis-induced severe immunosuppression, and results in the
342 possibility of reducing the risk of secondary infection. We further study to elucidate the molecular
343 mechanism by which IL-15 prevents sepsis-induced immunosuppression for a long time.

344 Our data indicate that aged septic mice display more severe T cell exhaustion than young
345 mice. The function of the acquired immune system decreases with age. This can be problematic
346 since the initial response to sepsis may be important. Data have indicated that increased mortality
347 is associated with a failure of protective immunity, with aged mice reported to display a failure of

348 innate immune response against sepsis, with no failure seen in young mice (35). Presently, IL-15
349 increased splenic NK cells, which play a role in initiating the host defense and coordinating innate
350 and adaptive immune response by producing IFN- γ and TNF- α , and also enhanced phagocytic
351 activity in aged septic mice (Supplemental Figure 1B and 1D). These results indicate that the
352 inhibition of severe and prolonged T cell exhaustion by IL-15 occurs via activation of innate
353 immune cells, such as NK cells and macrophages in aged mice and results in an increased survival
354 rate of aged septic mice from 70% to 100% (Figure 1C).

355 In conclusion, sepsis induced T cell exhaustion was more severe and prolonged in aged mice.
356 IL-15 could improve sepsis-induced T exhaustion by increasing the frequency of naïve CD4⁺ and
357 CD8⁺ T cell distribution and down-regulating the expression of PD-1 on T cell and Treg
358 population, with increasing NK cells and macrophage and phagocytosis activity in aged septic
359 mice. IL-15 may potentially improve T cell exhaustion over an extended period.

360

361

ACKNOWLEDGMENTS

362

This study was supported by the Teaching and Research Support Center of the School of

363

Medicine of Tokai University. We are thankful to Dr. Yoshiaki Okada and Yumiko Iida for

364

extensive technical support and advice on flow cytometric analysis. We are thankful to Nobuo

365

Watanabe, Yoshiko Shinozaki, Katsuko Naito and Kayoko Iwao for extensive support during

366

mouse-handling and observation of animal health.

367

We are thankful to Kazumichi Fujioka (Department of Pediatrics, Kobe University

368

Hospital), Takashi Matozaki and Yasuyuki Saito (Division of Molecular and Cellular Signaling,

369

Department of Biochemistry and Molecular Biology, Kobe University Graduate School of

370

Medicine) for extensive technical support and advice on flow cytometric analysis.

371

372

REFERENCES

373

- 374 1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo
375 R, Bernard GR, Chiche JD, Coopersmith CM, et al: The Third International Consensus
376 Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 315 (8):801-810, 2016.
- 377 2. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, Angus DC,
378 Reinhart K: International Forum of Acute Care Trialists: Assessment of global incidence and
379 mortality of hospital-treated sepsis: current estimates and limitations. *Am J Respir Crit Care*
380 *Med* 193(3): 259-272, 2016.
- 381 3. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States
382 from 1979 through 2000. *N Engl J Med* 348:1546–1554, 2003.
- 383 4. Inoue S, Suzuki-Utsunomiya K, Okada Y, Taira T, Iida Y, Miura N, Tsuji T, Yamagiwa T,
384 Morita S, Chiba T, Sato T, Inokuchi S: Reduction of immunocompetent T cells followed by
385 prolonged lymphopenia in severe sepsis in in the elderly. *Crit Care Med* 41(3): 810-819,
386 2013.
- 387 5. Hotchkiss RS, Monneret G, Payen D: Sepsis-induced immunosuppression: from cellular

- 388 dysfunctions to immunotherapy. *Nat Rev Immunol* 13: 862–874, 2013.
- 389 6. Inoue S, Suzuki-Utsunomiya K, Okada Y, Iida Y, Taira T, Miura N, Tsuji T, Yamagiwa T,
390 Morita S, Chiba T, et al: Reduction of immunocompetent T cells followed by prolonged
391 lymphopenia in severe sepsis in the elderly. *Crit Care Med* 41:810–819, 2013.
- 392 7. Wherry EJ, Kurachi M: Molecular and cellular insights into T cell exhaustion. *Nat Rev*
393 *Immunol* 15(8): 486-499, 2015.
- 394 8. Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, Moldawer LL, Moore
395 FA: Persistent inflammation and immunosuppression: A common syndrome and new horizon
396 for surgical intensive care. *J Trauma Acute Care Surg* 72(6): 1491-1501, 2012.
- 397 9. Chang K, Svabek C, Vazquez-Guillamet C, Sato B, Rasche D, Wilson S, Robbins P,
398 Ulbrandt N, Suzich J, Green J, et al: Targeting the programmed cell death 1: programmed
399 cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. *Crit Care* 18:
400 R3, 2014.
- 401 10. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, Ma A: IL-15 receptor
402 maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation.
403 *Immunity* 9: 669-676, 1998.

- 404 11. Berard M, Brandt K, Paus SB, and Tough DF: IL-15 promotes the survival of naive and
405 memory phenotype CD8⁺ T cells. *J Immunol* 170: 5018-5026, 2003.
- 406 12. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier
407 K, Sedger L, Willis CR, et al: Reversible defects in natural killer and memory CD8⁺ T cell
408 lineages in interleukin 15-deficient mice. *J Exp Med* 191(5):771–780. 2000.
- 409 13. Boyman O, Krieg C, Homann D, Sprent J: Homeostatic maintenance of T cells and natural
410 killer cells. *Cellu Mol Life Sci* 69(10):1597–1608. 2012.
- 411 14. Inoue S, Unsinger J, Davis CG, Muenzer JT, Ferguson TA, Chang K, Osborne DF, Clark AT,
412 Coopersmith CM, McDunn JE, et al: IL-15 prevents apoptosis, reverses innate and adaptive
413 immune dysfunction, and improves survival in sepsis. *J Immunol* 184: 1401-1409, 2010.
- 414 15. Wynn JL, Scumpia PO, Delano MJ, O'Malley KA, Ungaro R, Abouhamze A, Moldawer LL:
415 Increased mortality and altered immunity in neonatal sepsis produced by generalized
416 peritonitis. *Shock* 28: 675-683, 2007.
- 417 16. Starr ME, Steele AM, Saito M, Hacker BJ, B. Evers BM, Saito H: A new cecal slurry
418 Preparation protocol with improved long-term reproducibility for animal models of sepsis.
419 *PLoS ONE* 9 (12): e115705, 2014.

- 420 17. Gentile LF, Nacionales DC, Lopez MC, Vazant E, Cuenca A, Cuenca AG, Ungaro R, Szpila
421 BE, Larson S, Joseph A, et al: Protective immunity and defects in the neonatal and elderly
422 immune response to sepsis. *J Immunol* 192:3156-3165, 2014.
- 423 18. Osuchowski MF, Ayala A, Bahrami S, Bauer M, Boros M, Cavaillon JM, Chaudry IH,
424 Coopersmith CM, Deutschman C, Drechsler S, et al: Minimum quality threshold in pre-
425 clinical sepsis studies (MQTiPSS): an international expert consensus initiative for
426 improvement of animal modeling in sepsis. *Int Care Med Exp* 6:26, 2018.
- 427 19. Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical
428 statistics. *Bone Marr Transpla* 48: 452-458, 2013.
- 429 20. Weng NP: Aging of the immune system: how much can the adaptive immune system adapt?
430 *Immunity* 24: 495-499, 2006.
- 431 21. Hakim FT Gress RE: Immunosenescence: deficits in adaptive immunity in the elderly. *Tissue*
432 *Antigens* 70: 179-189, 2007.
- 433 22. Prescott HC, Langa KM, Iwashyna TJ: Readmission diagnoses after hospitalization for sever
434 sepsis and other acute medical conditions. *JAMA* 313 (10):1055-1057, 2015.
- 435 23. Prescott HC, Osterholzer JJ, Langa KM, Angus DC, Iwashyna TJ: Late mortality after sepsis:

- 436 propensity matched cohort study. *BMJ* 353: i2375, 2016.
- 437 24. Iwashyna TJ, Ely EW, Smith DM, Langa KM: Long-term cognitive impairment and
438 functional disability among survivors of severe sepsis. *JAMA* 304 (16):1787-1794, 2010.
- 439 25. Rossi DJ, Seita J, Czechowicz A, Bhattacharya D, Bryder D, Weissman IL: Hematopoietic
440 stem cell quiescence attenuates DNA damage response and permits DNA damage
441 accumulation during aging. *Cell cycle* 6 (19) :2371-2376, 2007.
- 442 26. Rossi DJ, Bryder D, Weissman IL: Hematopoietic stem cell aging: Mechanism and
443 consequence. *Exp Gerontol* 42 (5): 385-390, 2007.
- 444 27. Gallimore A, Glithero A, Godkin A, Tissot AC, Pluckthun A, Elliott T, Hengartner H,
445 Zinkernagel R: Induction and exhaustion of lymphocytic choriomeningitis virus-specific
446 cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility
447 complex class I-peptide complexes. *J Exp Med* 187:1383–1393, 1998.
- 448 28. Shimada Y, Hayashi M, Nagasaka Y, Ohno-Iwashita Y, Inomata M: Age-associated up-
449 regulation of a negative co-stimulatory receptor PD-1 in mouse CD4⁺ T cells. *Exp Gerontol*
450 44:517-522, 2009.
- 451 29. Shimatani K, Nakashima Y, Hattori M, Hamazaki Y, Minato N: PD-1⁺ memory phenotype

- 452 CD4⁺ T cells expressing C/EBP α underlie T cell immunodepression in senescence and
453 leukemia. *Proc Natl Acad Sci USA* 106:15807-15812, 2009.
- 454 30. Venet F, Chung CH, Kherouf H, Geeraert A, Malcus C, Poitevin F, Bohe' J, Lepape A, Ayala
455 A, Monneret G: Increased circulating regulatory T cells (CD4⁺ CD25⁺ CD127⁻) contribute to
456 lymphocyte anergy in septic shock patients. *Intensive Care Med* 35: 678-686, 2009.
- 457 31. Nascimento DC, Melo PH, Pineros AR, Ferreira RG, Colon DF, Donate PB, Castanheira FV,
458 Gozzi A, Czaikoski PG, Niedbala W, et al: IL-33 contributes to sepsis-induced long-term
459 immunosuppression by expanding the regulatory T cell population. *Nat Commun* 8: 14919,
460 2017.
- 461 32. Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA: Selective effects of PD-1 on
462 Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell
463 proliferation. *Sci Signal* 5: ra46, 2012.
- 464 33. Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya K, Ortaldo JR, Gupta
465 S, Chen YQ, Giri JD: Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus
466 kinases by interleukins 2 and 15. *Proc Natl Acad Sci U S A* 92: 8705–8709, 1995.
- 467 34. Wong HC, Jeng EK, Rhode PR: The IL-15-based superagonist ALT-803 promotes the

468 antigen-independent conversion of memory CD8⁺ T cells into innate-like effector cells with
469 antitumor activity. *Oncoimmunol* 2 (11): e26442, 2013.

470 35. Nacionales DC, Gentile LF, Vanzant E, Lopez MC, Cuenca A, Cuenca AG, Ungaro R, Li Y,
471 Baslanti TO, Bihorac A, et al: Aged mice are unable to mount an effective myeloid response
472 to sepsis. *J Immunol* 192 (2): 612-622, 2014.

473

474

Figure Legends

475

476 **Figure 1. Administration of IL-15 attenuates body weight loss and improves survival in**
477 **sepsis-induced mice.**

478 A) Schematic figure of the sepsis model generated using CS and treatment of IL-15 in this study
479 (Experiment 1). Sepsis- induced female young (6 weeks-old) and aged (18-24 months-old)
480 C57BL/6N mice were treated with or without 1.5 μ g of mouse recombinant IL-15 by
481 subcutaneous injection at day 3, 7 and 10.

482 B) Effect of administration with/without IL-15 on body weight in young and aged mice. Young
483 slurry: slurry-injected young mice without IL-15 treatment (n = 11, blue broken line and open
484 circle); Young slurry+IL-15: slurry-injected young mice with IL-15 treatment (n = 8, blue line
485 and closed circle). Aged slurry: slurry-injected aged mice without IL-15 treatment (n = 13, red
486 broken line and open triangle); Aged slurry+IL-15: slurry-injected aged mice with IL-15 treatment
487 (n = 6, red line and closed triangle).

488 C) Survival study of with/without IL-15-treated mice monitored for 50 days after sepsis induction.

489 The data are expressed as means \pm SD from three individual experiments. *, $p < 0.05$, **, $p < 0.01$.

490

491 **Figure 2. Effect of IL-15 on CD4⁺ T cells and its subpopulation after inducing sepsis.**

492 Peripheral blood was collected from their cheek at various timepoints and separated to perform

493 FACS analysis of peripheral CD4⁺ T cells. A) Gating strategy used for the identification of CD4⁺

494 and CD8⁺ T cells and their subpopulations in mouse peripheral blood leukocytes. B) CD4⁺ T cells,

495 C) percentage of CD62L^{High} within CD4⁺ T cells: naïve CD4⁺ T cells, D) PD-1⁺ within CD4⁺ T

496 cells, and E) Tregs (CD25⁺ CD127⁻ within CD4⁺ T cells) were analyzed by flow cytometry. Young

497 slurry: slurry-injected young mice without IL-15 treatment (n = 11, blue broken line and open

498 circle); Young slurry+IL-15: slurry-injected young mice with IL-15 treatment (n = 8, blue line

499 and closed circle). Aged slurry: slurry-injected aged mice without IL-15 treatment (n = 13, red

500 broken line and open triangle); Aged slurry+IL-15: slurry-injected aged mice with IL-15 treatment

501 (n = 6, red line and closed triangle).

502 The data are expressed as the means ± SD from three individual experiments. *, $p < 0.05$, **, p

503 < 0.01 .

504

505 **Figure 3. Effect of IL-15 on CD8⁺ T cell and its subpopulation after inducing sepsis**

506 Mice blood was from their cheek at indicated times and separated to perform FACS analysis of
507 peripheral CD8⁺ T cells. A) CD8⁺ T cells, B) percentage of CD62L^{High} within CD8⁺ T cells: naïve
508 CD8⁺ T cells, and C) PD-1⁺ within CD8⁺ T cells were analyzed by flowcytometry. Young slurry:
509 slurry-injected young mice without IL-15 treatment (n = 11, blue broken line and open circle);
510 Young slurry+IL-15: slurry-injected young mice with IL-15 treatment (n = 8, blue line and closed
511 circle). Aged slurry: slurry-injected aged mice without IL-15 treatment (n = 13, red broken line
512 and open triangle); Aged slurry+IL-15: slurry-injected aged mice with IL-15 treatment (n = 6, red
513 line and closed triangle).

514 The data are expressed as the means ± SD from three individual experiments. *, $p < 0.05$, **, p
515 < 0.01 .

516

517 **Supplemental Figure 1. IL-15 increases spleen CD4 T cells and NK cells and enhances**
518 **phagocytosis activity in aged mice**

519 A) Schematic diagram of the sepsis model generated using CS and treatment of IL-15
520 (Experiment 2). Sepsis-induced, female, young (6 weeks-old) and aged (18 months-old)
521 C57BL/6N mice were untreated or treated with 1.5 µg mouse recombinant IL-15 by subcutaneous

522 injection at day 3, 7, and 10. Young and aged mice injected 50 μ L CS and were sacrificed 12 days
523 after (Experiment 2). B) Spleens were harvested, and the distribution of T cells and NK cells
524 (defined as CD3⁻NK1.1⁺) in those tissues was analyzed by flow cytometry. C, D) Peritoneal lavage
525 was aseptically collected. C) Proportion of macrophages in PBMCs. D) Separated peritoneal
526 lavage cells were cultured with PE-labeled *E. coli* beads for 30 min to evaluate the phagocytic
527 activity. E) Bacterial colonies were determined from serial dilutions of peritoneal lavage fluid.
528 The data are expressed as the mean \pm SD from three individual experiments. *, $p < 0.05$, **, p
529 < 0.01